ITP approach

Reading File

Finding Sources

Searching PubMed

"immune thrombocytopenia" AND management

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

I now have comprehensive material from multiple authoritative textbooks. Let me compile the full clinical approach to ITP.

Immune Thrombocytopenia (ITP) - Clinical Approach

Definition & Diagnosis Threshold

ITP is an autoimmune disorder in which circulating antiplatelet autoantibodies lead to premature platelet destruction. The international consensus threshold for diagnosis is a platelet count <100,000/μL in the absence of other causes. Importantly, ITP is a diagnosis of exclusion - other causes must first be ruled out.

Classification

Type	Features
Primary (Idiopathic)	No identifiable underlying cause
Secondary	Associated with SLE, HIV, CLL, other lymphoproliferative disorders
Acute ITP	Mainly children; follows viral illness; self-limited (usually resolves within 6 months)
Chronic ITP	Adults; >12 months duration; relapsing course in most

Pathophysiology

Autoantibodies (mainly IgG) target platelet membrane glycoproteins IIb/IIIa or Ib/IX in ~80% of patients
Antibody-coated platelets are opsonized and removed by Fc receptor-bearing phagocytes, predominantly in the spleen
In ~50% of cases, antiplatelet antibodies cannot be demonstrated - T-cell mediated mechanisms and CD8+ cell involvement also play roles
Antibodies may also bind megakaryocytes, impairing platelet production
The spleen is both the primary site of platelet destruction AND a major source of autoantibody production (splenic plasma cells)

Clinical Features

Who gets it:

Bimodal distribution: peak 1 at ages 20-30 (females > males, 3:1 ratio); peak 2 after age 60 (no sex difference)
In children: equal sex frequency, acute course
In adults: chronic, relapsing course predominates

Bleeding pattern - mucocutaneous (platelet-type, not deep tissue):

Petechiae (especially dependent areas where capillary pressure is higher)
Ecchymoses, purpura
Epistaxis, gingival bleeding
Menorrhagia
Hematuria, melena/hematochezia
Serious: intracranial hemorrhage, retinal hemorrhage (rare but life-threatening)

What is ABSENT: splenomegaly and lymphadenopathy (if present, suspect secondary ITP from lymphoma or other underlying disease)

Diagnosis

The diagnosis is clinical and by exclusion.

Finding	In ITP
CBC	Isolated thrombocytopenia; otherwise normal
Peripheral blood smear	Decreased platelets, some larger than normal (megathrombocytes - sign of accelerated thrombopoiesis); NO schistocytes
PT/PTT	Normal
Bone marrow	Normal or increased megakaryocytes (reflects accelerated platelet destruction)
Spleen	Normal size in primary ITP

What NOT to do:

Antiplatelet antibody assays - low sensitivity AND specificity, not clinically useful
Bone marrow biopsy - not routinely required unless CBC shows other abnormalities or age >60 (to exclude myelodysplasia)

Key differentials to exclude:

Pseudothrombocytopenia (EDTA-induced platelet clumping on smear - recheck in citrate tube)
Drug-induced thrombocytopenia (quinine, quinidine, sulfonamides, β-lactams, vancomycin, heparin/HIT)
TTP/HUS (microangiopathic hemolytic anemia + schistocytes)
DIC, HIV, hepatitis C, SLE, gestational thrombocytopenia
Bone marrow failure, leukemia, lymphoma

When to Treat

Guidelines (Goldman-Cecil / ASH 2019):

Treatment should be given to newly diagnosed patients if platelets are <30,000/μL

Platelets >30,000/μL + no significant bleeding symptoms → observe without treatment (no increased mortality)
Platelets <30,000/μL OR any bleeding → treat
Severe ITP with acute hemorrhage → hospital admission + combined-modality emergency therapy

Treatment Algorithm

First-Line Therapy

Agent	Dose	Notes
Prednisone	1 mg/kg/day orally	~80% respond; relapse common on taper
Dexamethasone	40 mg/day × 4 days, every 28 days for several cycles	Higher initial response rate; better tolerated than prolonged prednisone
IVIG	1 g/kg/day × 2 days, or 0.4 g/kg/day × 5 days	Response ~80%; faster than prednisone; lasts 2-4 weeks; use when rapid rise needed
Anti-D (Rh₀(D) immune globulin)	50-75 μg/kg IV	Only in Rh-positive, non-splenectomized patients; works by saturating Fc receptors; monitor 8h post-infusion for hemolysis
Mycophenolate mofetil	Under expert supervision	Emerging as an alternative first-line

IVIG should be added to corticosteroids when a rapid rise in platelet count is required
If steroids are contraindicated, use IVIG or anti-D as first-line alternatives

For acute hemorrhage or severe ITP → combine high-dose glucocorticoids + IVIG + platelet transfusion ± additional immunosuppressives

Second-Line Therapy

(For patients unresponsive to, or relapsing after, initial corticosteroid course)

1. Rituximab (anti-CD20)

375 mg/m² IV weekly × 4 weeks
Significant response in ~60% of patients
Complete response ~40%; durable long-term remission in only ~30%
Combination with dexamethasone gives higher response rates
Takes ≥3 weeks to work - bridge with steroids if profoundly thrombocytopenic
Risks: hepatitis B reactivation, immunosuppression, rare PML

2. TPO Receptor Agonists (TPO-RAs) - first choice for chronic ITP

Romiplostim (subcutaneous, weekly): start 2-3 μg/kg → titrate up to 10 μg/kg/week
Eltrombopag (oral, daily): 50 mg/day (25 mg in East Asian ancestry or liver insufficiency)
Avatrombopag (oral, daily): 20 mg/day
Response in 70-90% of patients; effective even in splenectomized patients
Effect appears in 2-3 weeks; disappears after stopping (except in some who achieve sustained off-treatment response)
Risks: bone marrow fibrosis (long-term), thromboembolism

3. Splenectomy

Durable response in 65-70% of patients (often lifelong); partial benefit in another 10-15%
No reliable predictor of response
Reserve for patients requiring treatment for >12 months (or failure of other therapies)
Pre-operative vaccines required: pneumococcus, meningococcus, H. influenzae (at least 2 weeks before)
Risks: surgical morbidity/mortality (~1-2%), lifelong susceptibility to encapsulated organisms, small long-term thrombosis risk
Now used less frequently compared to TPO-RAs due to side effects and quality of life impact

Refractory ITP

If patients fail splenectomy or all second-line agents:

Continue TPO-RAs (effective even post-splenectomy)
Low-dose prednisone as maintenance (e.g., 5 mg/day)
Additional immunosuppressants: azathioprine, cyclophosphamide
Fostamatinib (spleen tyrosine kinase inhibitor) - FDA-approved for chronic ITP refractory to other treatments
Combination immunotherapy approaches

Special Situations

Scenario	Approach
Emergency bleeding/intracranial hemorrhage	Platelet transfusion + IVIG + high-dose steroids ± emergent splenectomy
Pregnant patient	Manage with IVIG/steroids; avoid anti-D in Rh- mothers
Pediatric acute ITP	Most self-resolve; treat only if severe thrombocytopenia
HIV-related	Treat underlying HIV; ITP often improves with antiretroviral therapy
Secondary ITP (SLE, CLL)	Treat underlying disease + ITP-specific therapy
Post-splenectomy relapse	Accessory spleen (rare) - check with imaging; then TPO-RA or rituximab

Key Platelet Count Thresholds - Quick Reference

Platelet Count	Risk	Action
50,000-150,000/μL	Mild thrombocytopenia	Observe if asymptomatic
20,000-50,000/μL	Increased risk of post-traumatic bleeding	Treat if symptomatic
<30,000/μL	Threshold for treatment per guidelines	Start treatment
<5,000-10,000/μL	Risk of spontaneous bleeding	Urgent treatment
<5,000/μL	High risk of spontaneous hemorrhage	Emergency treatment

Sources

Harrison's Principles of Internal Medicine 22E (2025)
Goldman-Cecil Medicine, International Edition
Robbins, Cotran & Kumar Pathologic Basis of Disease
Mulholland and Greenfield's Surgery, 7e
Robbins & Kumar Basic Pathology

Recent evidence update: A 2025 network meta-analysis (PMID 40547032) on TPO-RA comparisons in pediatric ITP found romiplostim, eltrombopag, and rhTPO to all be effective options; a 2025 systematic review (PMID 39552264) addressed critical bleeds in ITP.

This is a shared conversation. Sign in to Orris to start your own chat.